Gilead Sciences Earnings: What to Watch

Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Last year, Gilead’s Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September. The fourth-quarter results will give a hint how Gilead’s newest hepatitis C pill, Harvoni, approved Oct. 10, will fare. So far, the signs are positive: insurance claims data from Symphony Health Solutions indicate Harvoni’s launch during its first 14 weeks on sale is at a higher volume than Sovaldi’s.

[button title=”read more” link=”http://blogs.wsj.com/corporate-intelligence/2015/02/02/gilead-sciences-earnings-what-to-watch-2/” target=”_blank” size=”” color=”” class=””]